[Baili Tianheng: The first subject has been enrolled in the phase III clinical trial of T-Bren combined with pertuzumab] On September 13, Baili Tianheng (688506.SH) announced that the company’s independently developed innovative biologic drug T-Bren for Injection The phase III randomized controlled clinical trial of Bren (HER2ADC) combined with pertuzumab compared with docetaxel + carboplatin + trastuzumab + pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer has completed the enrollment of the first subject. As of now, T-Bren is conducting 20 clinical trials at home and abroad, covering multiple indications such as breast cancer, gastric cancer, lung cancer, digestive tract tumors, urinary system tumors, and gynecological tumors.